Oslo, Norway, 5 November 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its executive management team will participate in the following upcoming investor conferences:
Credit Suisse Healthcare Conference 2013
|
|
Date: 12-14 November 2013
|
|
Participants:
|
| |
Jeff Albers (President, Algeta US)
|
| |
Mike Booth (SVP, Communications)
|
|
Venue: Scottsdale, AZ, USA
|
DNB Markets Health Care Conference
|
|
Date: 27 November 2013
|
|
Participants:
|
| |
Andrew Kay (President & CEO)
|
| |
Thomas Ramdahl (Executive VP and COO)
|
|
Venue: Oslo, Norway
|
Deutsche Bank dbAccess Pharmaceutical Corporate Day
|
|
Date: 5 December 2013
|
|
Participants:
|
| |
Andrew Kay (President & CEO)
|
| |
Mike Booth (SVP, Communications)
|
|
Venue: London, UK
|
SEB Securities Best of Norway Day
|
|
Date: 12 December 2013
|
|
Participants:
|
| |
Mike Booth (SVP, Communications)
|
|
Venue: New York, NY, USA
|
Presentations, where applicable, will be available to download at www.algeta.com following these events.
###
For further information, please contact:
Mike Booth
|
+1 646 410 1884
|
Communications & Corporate Affairs
| ir@algeta.com |
| |
Media enquiries: | |
Mark Swallow
|
+44 207 638 9571
|
Citigate Dewe Rogerson
| mark.swallow@citigatedr.co.uk |
| |
Knut Ekern
|
+47 22 04 82 00
|
Gambit Hill & Knowlton
| knut.ekern@hkstrategies.com |
| |
Kari Watson
|
+1 781 235 3060
|
MacDougall Biomedical Communications
| kwatson@macbiocom.com |
| |
Investor enquiries: | |
Tricia Truehart
|
+1 646 378 2953
|
The Trout Group
| ttruehart@troutgroup.com |
About Algeta
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
distributed by
| |